GET THE APP

Journal of Blood & Lymph

Journal of Blood & Lymph

ISSN: 2165-7831

Open Access

Articles in press and Articles in process

    Research Pages: 1 - 5

    Clinical and Biological Profile and Factors Associated with High Blood Lead Levels in Chronic Hemodialysis Patients in a Western French Guiana Hospital Center

    Arriel Makembi Bunkete1* , Florence Fermigier 1 , David Gondele Ipungu 1 , Kazi Anga Muamba 1 , Blady Mpibi Mpiana 1 , Alphonse Edjokola Munyubu1 , Gabriel Bafunyembaka1 , Pascal Kuamba Kasonga1 , Franchisca-Anaïs Morry 1 , Yannick Kashala Madimba 1 , Mohamed Sidibe2 , Malika Belgrine2 , Timote Davodoun2 , Irenée Djiconkpode 1 and Tanguy Gbaguidi2

    Background: Lead is toxic to the body. Its chronic intoxication combines various clinical and biological disorders that can be life-threatening. In French Guiana, lead poisoning is particularly worrying, as the incidence rate is nearly sixty times higher than in metropolitan France. In chronic hemodialysis patients, lead levels are often higher and can lead to several adverse consequences. Hence, the interest of this study, which is to describe the clinical and biological characteristics of chronic hemodialysis patients with high blood lead levels and to identify the associated factors to draw attention to its screening and the prevention of its complications. Methods: Descriptive and analytical cross-sectional study that included 65 patients on chronic conventional hemodialysis: With an annual biological assessment in December 2022, including a serum lead assay. The outcome was the notion of hyper lead level, defined by a lead level >85 μg/l. We described the clinical, biological, and dialytic parameters of patients with hyper lead levels and in logistic regression, we identified the factors that are correlated according to a significance threshold P<0.05. Results: In all, 54% of patients had hyperplumbemia, 2/3 of them women. They were older, with an average age of 62. None of the patients had been occupationally exposed to lead. 94% were hypertensive and half were diabetic. 26% had anemia, and half had erythropoietin resistance. Their ferritin levels were slightly lower, with a mean of 721 μg/l. Mean albumin was 30 g/l, prealbumin 28 g/l, mean parathyroid hormone 1355 ng/ml, NT-pro BNP 9144 ng/ml. Mean CRP was 10.8 mg/l. They had collapsed residual diuresis and natriuresis with averages of 141 ml and 12 mmol/24 hours, respectively. There was a significant positive correlation between high Blood Lead Level (BLL) levels and young age, and a negative correlation with female gender, low serum albumin, prealbumin, protein and ferritin levels, as well as collapsed residual diuresis. Conclusion: High blood lead levels are common in the Guyanese chronic hemodialysis population in which it is correlated with female sex, malnutrition, iron deficiency and residual poor renal function and probably with resistance to erythropoietin treatment. It is necessary to screen in at-risk populations to prevent complications associated with it.

    Mini Review Pages: 1 - 3

    The Potential of 3,6-Anhydro-L-Galactose (L-AHG) as a Novel Immunosuppressant

    Shin Young Park, Ki Yun Kim, Young-Seuk Bae, Do Youn Jun and Young Ho Kim*

    3,6-Anhydro-L-Galactose (L-AHG), a bioactive carbohydrate derived from agarose extracted from red algae, is produced via a two- step enzymatic hydrolysis process, yielding high purity. It effectively inhibits the proliferation of activated T and B lymphocytes, key players in adaptive immunity, by suppressing the Janus Kinase-Signal Transducer and Activator of Transcription (JAK-STAT) signaling pathway and blocking the G1-S traverse in the cell cycle. This dual mechanism reduces adaptive immune responses, positioning L- AHG as a next-generation immunosuppressant. Its targeted approach promises greater safety and efficacy compared to traditional therapies, with potential applications in autoimmune disease treatment, transplant rejection prevention and managing hyperactive immune responses. This review presents detailed insights into the production process, mechanisms of action and therapeutic possibilities of L-AHG, highlighting its capacity to address many of the shortcomings of current immunosuppressive drugs.

Google Scholar citation report
Citations: 443

Journal of Blood & Lymph received 443 citations as per Google Scholar report

Journal of Blood & Lymph peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward